Industry

FDA approves extension of Eylea HD dosing intervals

Healio Ophthalmology3d ago1 min read

The FDA approved an extension of dosing intervals for Eylea HD in patients with diabetic macular edema and wet age-related macular degeneration, Regeneron Pharmaceuticals, Inc. announced.The approval, which extended the dosing intervals up to every 20 weeks, also includes an update to the Eylea HD (aflibercept 8 mg, Regeneron) label to include 2-year data from “the pivotal” PULSAR and PHOTON trials, according to a press release.“The potential for needing only two or three Eylea HD injections a year to manage certain retinal diseases is an exciting advance that could benefit

Read full article on Healio Ophthalmology

AI Summary

Quick Take

The FDA has approved a dosing interval extension for Eylea HD (aflibercept 8 mg), allowing patients with wet age-related macular degeneration and diabetic macular edema to be treated as infrequently as every 20 weeks. This update incorporates two-year data from the pivotal PULSAR and PHOTON trials, potentially reducing the treatment burden to just two or three injections per year for many patients.

Why It Matters

Treatment fatigue is a major factor in sub-optimal real-world outcomes for retinal diseases, as frequent injection schedules are difficult for patients and caregivers to maintain. By extending the interval to 20 weeks—nearly five months—Eylea HD provides a significant durability advantage that may improve long-term compliance and clinic efficiency. This approval reinforces the shift toward high-dose anti-VEGF therapies as a standard for reducing the frequency of invasive ocular procedures without sacrificing visual gains.

Key Findings

FDA approval extends Eylea HD (aflibercept 8 mg) dosing intervals up to every 20 weeks for DME and wet AMD.
The Eylea HD label now includes two-year data from the pivotal PULSAR and PHOTON clinical trials.
The extended interval allows for a maintenance schedule of as few as two to three injections per year.
The approval applies specifically to patients with diabetic macular edema (DME) and wet age-related macular degeneration (wAMD).

Study Snapshot

Design

Pivotal clinical trials (PULSAR and PHOTON)

Population

Patients with wet age-related macular degeneration and diabetic macular edema

Practice Implications

Retinal specialists can now officially extend stable patients to a five-month treatment cycle using the 8 mg formulation, which may help alleviate high patient volumes in busy practices. When managing DME and wet AMD, clinicians should evaluate if patients currently on shorter intervals can be transitioned to Eylea HD to reduce the frequency of office visits and injections.

Who's Affected

Retina SpecialistsOphthalmologistsPractice Owners

Evidence StrengthStrong

AI-generated summary — always read the original source for full context

Discussion

No comments yet. Be the first to share your thoughts.